Filing Details

Accession Number:
0001062993-23-002790
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-02-10 21:47:40
Reporting Period:
2023-02-08
Accepted Time:
2023-02-10 21:47:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
886744 Geron Corp GERN Pharmaceutical Preparations (2834) 752287752
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1270928 A John Scarlett C/O Geron Corporation
919 E. Hillsdale Blvd, Suite 250
Foster City CA 94404
Chairman, President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2023-02-08 446,666 $1.50 446,666 No 4 M Direct
Common Stock Disposition 2023-02-08 446,666 $3.08 0 No 4 S Direct
Common Stock Acquisiton 2023-02-09 446,666 $1.50 446,666 No 4 M Direct
Common Stock Disposition 2023-02-09 446,666 $3.03 0 No 4 S Direct
Common Stock Acquisiton 2023-02-10 446,668 $1.50 446,668 No 4 M Direct
Common Stock Disposition 2023-02-10 446,668 $3.00 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (right to buy) Disposition 2023-02-08 446,666 $0.00 446,666 $1.50
Common Stock Employee Stock Option (right to buy) Disposition 2023-02-09 446,666 $0.00 446,666 $1.50
Common Stock Employee Stock Option (right to buy) Disposition 2023-02-10 446,668 $0.00 446,668 $1.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2023-02-13 No 4 M Direct
0 2023-02-13 No 4 M Direct
0 2023-02-13 No 4 M Direct
Footnotes
  1. Option was fully vested.
  2. These transactions reflect exercises and sales of options due to expire on February 13, 2023 and were conducted pursuant to an approved 10b5-1 trading plan adopted by the reporting person on January 9, 2023.